|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20030157108A1
(en)
*
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
TW200515915A
(en)
*
|
2002-11-08 |
2005-05-16 |
Wackvom Ltd |
Extract of Trapa natans and methods of using the same
|
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
PT1771474E
(pt)
|
2004-07-20 |
2010-05-03 |
Genentech Inc |
Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização
|
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
|
BRPI0518105A
(pt)
*
|
2004-12-17 |
2008-11-04 |
Genentech Inc |
uso de antagonista da angiogênese e uso de anticorpo anti-vegf
|
|
FR2893622B1
(fr)
|
2005-11-24 |
2007-12-21 |
Commissariat Energie Atomique |
Composition a base de caprolactame,procede de fabrication d'un element d'etancheite,et reservoir
|
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
AU2012204022C1
(en)
*
|
2005-12-02 |
2014-02-20 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
CN101370832B
(zh)
*
|
2005-12-02 |
2014-07-02 |
健泰科生物技术公司 |
结合多肽及其用途
|
|
EP1957540B1
(en)
|
2005-12-02 |
2012-06-13 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
JP2009518024A
(ja)
*
|
2005-12-06 |
2009-05-07 |
ドマンティス リミテッド |
Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
|
|
KR101538521B1
(ko)
|
2005-12-15 |
2015-07-22 |
제넨테크, 인크. |
폴리유비퀴틴 표적화를 위한 방법 및 조성물
|
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
|
CA2638823A1
(en)
|
2006-02-13 |
2007-08-23 |
Alethia Biotherapeutics Inc. |
Polynucleotides and polypeptide sequences involved in the process of bone remodeling
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
AR060040A1
(es)
|
2006-03-21 |
2008-05-21 |
Genentech Inc |
Antagonistas de vefg y de alfa5 beta 1
|
|
WO2007139359A1
(en)
*
|
2006-05-31 |
2007-12-06 |
Hanwha Chemical Corporation |
Vcam-1 specific monoclonal antibody
|
|
RU2415869C2
(ru)
*
|
2006-06-06 |
2011-04-10 |
Дженентек, Инк. |
Антитела против dll4 и способы их применения
|
|
CA2654000A1
(en)
*
|
2006-06-06 |
2008-05-22 |
Genentech, Inc. |
Anti-dll4 antibodies and methods using same
|
|
BRPI0715829A2
(pt)
*
|
2006-08-21 |
2013-07-23 |
Hoffmann La Roche |
terapia de tumor com um anticorpo anti-vegf
|
|
EP2059533B1
(en)
*
|
2006-08-30 |
2012-11-14 |
Genentech, Inc. |
Multispecific antibodies
|
|
CA2664738C
(en)
|
2006-09-29 |
2017-03-07 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
WO2008100292A2
(en)
|
2006-10-16 |
2008-08-21 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
|
CU23636A1
(es)
|
2006-11-01 |
2011-03-21 |
Ct Ingenieria Genetica Biotech |
Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
|
|
SI2099489T1
(sl)
*
|
2006-12-11 |
2014-09-30 |
Genentech, Inc. |
Sestavki in postopki za zdravljenje neoplazme
|
|
HUE029445T2
(en)
*
|
2006-12-19 |
2017-02-28 |
Genentech Inc |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
|
|
JP2010518013A
(ja)
*
|
2007-02-01 |
2010-05-27 |
ジェネンテック， インコーポレイテッド |
血管形成阻害剤を含む組み合わせ治療の方法
|
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Ｒｏｂｏ４ 항체 및 그의 용도
|
|
BRPI0807952A2
(pt)
|
2007-02-20 |
2014-06-10 |
Anaptysbio Inc |
Sistemas de hipermutação somática
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
US7977313B2
(en)
*
|
2007-04-27 |
2011-07-12 |
Affinergy, Inc. |
Methods and compositions for promoting localization of pharmaceutically active agents to bone
|
|
GB0709333D0
(en)
|
2007-05-15 |
2007-06-20 |
Smart Targeting Ltd |
Binding protein
|
|
JP2010530359A
(ja)
|
2007-05-17 |
2010-09-09 |
ジェネンテック， インコーポレイテッド |
ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
US20090011060A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Peter Koepke |
Campsiandra angustifolia extract and methods of extracting and using such extract
|
|
US7879369B2
(en)
|
2007-09-18 |
2011-02-01 |
Selvamedica, Llc |
Combretum laurifolium Mart. extract and methods of extracting and using such extract
|
|
CL2008003302A1
(es)
|
2007-11-09 |
2009-03-06 |
Genentech Inc |
Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos.
|
|
MX2010005104A
(es)
*
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
|
AU2013205269B2
(en)
*
|
2007-11-09 |
2016-05-19 |
Affitech Research As |
Anti-VEGF antibody compositions and methods
|
|
AU2015200714B2
(en)
*
|
2007-11-30 |
2017-01-12 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
AU2013204108B2
(en)
*
|
2007-11-30 |
2014-11-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
|
US8227577B2
(en)
*
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
CN101977934B
(zh)
|
2008-01-18 |
2014-09-17 |
健泰科生物技术公司 |
用于靶向k63连接的多聚遍在蛋白的方法和组合物
|
|
HUE035184T2
(en)
|
2008-03-18 |
2018-05-02 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
SI2274008T1
(sl)
*
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
|
JP5646457B2
(ja)
*
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
|
AR072000A1
(es)
|
2008-06-03 |
2010-07-28 |
Abbott Lab |
Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
|
|
HUE032894T2
(hu)
|
2008-06-25 |
2017-11-28 |
Esbatech Alcon Biomed Res Unit |
VEGF-gátló, stabilis és oldható antitestek
|
|
WO2010003118A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
|
BRPI0915448A2
(pt)
|
2008-07-08 |
2015-11-10 |
Abbott Lab |
imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
|
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
|
JP2012501188A
(ja)
*
|
2008-08-29 |
2012-01-19 |
ジェネンテック， インコーポレイテッド |
Ｖｅｇｆ非依存性腫瘍についての診断薬および治療
|
|
US8268314B2
(en)
*
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
EP3524620A1
(en)
|
2008-10-14 |
2019-08-14 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
WO2010056893A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Imclone Llc |
Humanization and affinity-optimization of antibodies
|
|
AR074203A1
(es)
*
|
2008-11-22 |
2010-12-29 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
|
|
JP5416221B2
(ja)
|
2008-12-23 |
2014-02-12 |
ジェネンテック， インコーポレイテッド |
癌患者における診断用途のための方法および組成物
|
|
AU2010229479B2
(en)
|
2009-03-25 |
2013-03-28 |
Genentech, Inc. |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
PE20120591A1
(es)
*
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
|
CN102369214B
(zh)
|
2009-04-07 |
2019-04-12 |
罗氏格黎卡特股份公司 |
三价、双特异性抗体
|
|
EA030182B1
(ru)
|
2009-04-20 |
2018-07-31 |
Оксфорд Байотерепьютикс Лтд. |
Антитела, специфические для кадгерина-17
|
|
AU2010239368A1
(en)
*
|
2009-04-20 |
2011-11-10 |
Genentech, Inc. |
Adjuvant cancer therapy
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
BR112012000735A2
(pt)
|
2009-07-13 |
2016-11-16 |
Genentech Inc |
"métodos, kits e conjuntos de compostos"
|
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
|
WO2011014750A1
(en)
*
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
|
AU2010282508B2
(en)
|
2009-08-13 |
2015-05-28 |
Crystal Bioscience Inc. |
Transgenic animal for production of antibodies having minimal CDRs
|
|
EP2464744A1
(en)
|
2009-08-14 |
2012-06-20 |
F. Hoffmann-La Roche AG |
Biological markers for monitoring patient response to vegf antagonists
|
|
BR112012003346A2
(pt)
|
2009-08-15 |
2016-11-16 |
Genentech Inc |
metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
|
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
CN102597776A
(zh)
|
2009-09-11 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌剂的可能性升高的患者的方法
|
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
JP5606537B2
(ja)
|
2009-09-17 |
2014-10-15 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌患者における診断使用のための方法及び組成物
|
|
CA2775765A1
(en)
|
2009-10-05 |
2011-04-14 |
Opsonic Therapeutics Inc. |
High affinity adaptor molecules for redirecting antibody specifity
|
|
TW201119676A
(en)
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US8883145B2
(en)
|
2009-10-16 |
2014-11-11 |
Oncomed Pharmaceuticals, Inc. |
Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
|
|
CA2859193C
(en)
*
|
2009-10-21 |
2023-02-07 |
Genentech, Inc. |
Genetic polymorphisms in age-related macular degeneration
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
SG181834A1
(en)
|
2009-12-21 |
2012-07-30 |
Genentech Inc |
Antibody formulation
|
|
JP5852010B2
(ja)
|
2009-12-23 |
2016-02-03 |
ジェネンテック， インコーポレイテッド |
抗Ｂｖ８抗体およびその使用
|
|
WO2011088111A1
(en)
*
|
2010-01-12 |
2011-07-21 |
Genentech, Inc. |
ANTI-PlGF ANTIBODIES AND METHODS USING SAME
|
|
CN110227154A
(zh)
|
2010-02-23 |
2019-09-13 |
霍夫曼-拉罗奇有限公司 |
用于治疗卵巢癌的抗血管发生疗法
|
|
CN102167740B
(zh)
*
|
2010-02-25 |
2014-06-04 |
上海百迈博制药有限公司 |
一种全人源抗vegf单克隆抗体、其制备方法及用途
|
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
US8992919B2
(en)
|
2010-04-15 |
2015-03-31 |
Genentech, Inc. |
Anti-polyubiquitin antibodies and methods of use
|
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
|
US8834883B2
(en)
|
2010-06-14 |
2014-09-16 |
Vaccinex, Inc. |
Anti-VEGF antibodies and uses thereof
|
|
BR112013001433A2
(pt)
|
2010-07-19 |
2016-05-31 |
Hoffmann La Roche |
método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
|
|
CN103109189A
(zh)
|
2010-07-19 |
2013-05-15 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
SG187938A1
(en)
|
2010-08-26 |
2013-04-30 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
SG189835A1
(en)
*
|
2010-10-20 |
2013-06-28 |
Oxford Biotherapeutics Ltd |
Antibodies
|
|
AR083819A1
(es)
|
2010-11-10 |
2013-03-27 |
Genentech Inc |
UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
|
|
NZ610487A
(en)
|
2010-11-15 |
2015-03-27 |
Five Prime Therapeutics Inc |
Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
|
|
JP2014501725A
(ja)
*
|
2010-11-24 |
2014-01-23 |
グラクソ グループ リミテッド |
Ｈｇｆを標的とする多特異的抗原結合タンパク質
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
CU23895B1
(es)
|
2010-12-28 |
2013-05-31 |
Biorec Sa |
Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
EP2670847B1
(en)
*
|
2011-02-03 |
2016-10-05 |
XOMA Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
CN103841975A
(zh)
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt抑制剂化合物和厄洛替尼的组合以及使用方法
|
|
CN108178789B
(zh)
|
2011-04-20 |
2021-11-02 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
|
WO2012151317A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Vascular disruption agents and uses thereof
|
|
BR112013030472A2
(pt)
|
2011-06-30 |
2019-09-24 |
Genentech Inc |
formulação farmacêutica, artigo de fabricação e método
|
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
|
US10466160B2
(en)
|
2011-08-01 |
2019-11-05 |
Celsee Diagnostics, Inc. |
System and method for retrieving and analyzing particles
|
|
ES2797448T3
(es)
|
2011-08-01 |
2020-12-02 |
Bio Rad Laboratories |
Sistema de captura de células
|
|
US9321844B2
(en)
|
2011-08-05 |
2016-04-26 |
Genentech, Inc. |
Anti-polyubiquitin antibodies
|
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
|
US20130078252A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
|
JP6170496B2
(ja)
|
2011-09-23 |
2017-07-26 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
|
|
TW201326193A
(zh)
|
2011-11-21 |
2013-07-01 |
Genentech Inc |
抗－ｃ－ｍｅｔ抗體之純化
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
WO2013083499A1
(en)
|
2011-12-05 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
|
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
|
CN104159920A
(zh)
|
2011-12-30 |
2014-11-19 |
艾伯维公司 |
针对il-13和/或il-17的双重可变结构域免疫球蛋白
|
|
BR112014017320A2
(en)
|
2012-01-13 |
2018-05-29 |
Genentech, Inc |
method for determining whether a patient is prone to respond to treatment with a vegf antagonist, method for optimizing the therapeutic efficacy of a vegf antagonist, method for selecting a therapy, method for identifying a biomarker, and method for diagnosing an angiogenic disorder
|
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
|
BR112014018964A2
(pt)
|
2012-03-13 |
2020-05-12 |
F. Hoffmann-La Roche Ag |
Anticorpo anti-vegf e uso de um anticorpo anti-vegf
|
|
MX2014011582A
(es)
|
2012-03-30 |
2014-11-21 |
Genentech Inc |
Metodos y composiciones de diagnostico para el tratamiento de cancer.
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
TWI641687B
(zh)
*
|
2012-05-29 |
2018-11-21 |
美商再生元醫藥公司 |
生產細胞株增強子
|
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
|
KR101915942B1
(ko)
|
2012-06-08 |
2018-11-06 |
에프. 호프만-라 로슈 아게 |
암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
|
|
WO2013188403A1
(en)
*
|
2012-06-11 |
2013-12-19 |
Syngenta Participations Ag |
Producing solids and related mother liquors
|
|
CN104364655A
(zh)
|
2012-06-26 |
2015-02-18 |
霍夫曼-拉罗奇有限公司 |
贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物
|
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
|
RU2015100656A
(ru)
|
2012-06-27 |
2016-08-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
|
|
EP2872534B1
(en)
|
2012-07-13 |
2018-08-08 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
ES2723885T3
(es)
|
2012-07-19 |
2019-09-03 |
Daiichi Sankyo Co Ltd |
Anticuerpos anti-Siglec-15
|
|
SG11201500903XA
(en)
|
2012-08-07 |
2015-03-30 |
Genentech Inc |
Combination therapy for the treatment of glioblastoma
|
|
BR112015003032B1
(pt)
*
|
2012-08-13 |
2023-03-28 |
Genentech, Inc |
Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
|
|
US12024568B2
(en)
|
2012-09-13 |
2024-07-02 |
Cornell University |
Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
|
|
JP6371294B2
(ja)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
|
|
MY171664A
(en)
|
2012-11-01 |
2019-10-22 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
|
|
US20140154255A1
(en)
*
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
|
WO2014106076A2
(en)
*
|
2012-12-28 |
2014-07-03 |
Quest Diagnostics Investments Incorporated |
Universal sanger sequencing from next-gen sequencing amplicons
|
|
SMT202000088T1
(it)
|
2013-02-18 |
2020-03-13 |
Vegenics Pty Ltd |
Molecole leganti ligandi e relativi usi
|
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
|
CN105209069B
(zh)
|
2013-03-13 |
2019-08-23 |
豪夫迈·罗氏有限公司 |
抗体配制剂
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
CN105339001A
(zh)
|
2013-03-15 |
2016-02-17 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
|
|
MX2015014181A
(es)
|
2013-04-09 |
2016-05-24 |
Boston Biomedical Inc |
2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
|
|
BR112015029145A2
(pt)
|
2013-05-23 |
2017-09-19 |
Glaxosmithkline Ip No 2 Ltd |
Usos de um domínio extracelular (ecd) de receptor de fator de crescimento de fibroblastos 1 (fgfr1) e métodos de identificação de pacientes
|
|
KR101541478B1
(ko)
|
2013-05-31 |
2015-08-05 |
동아쏘시오홀딩스 주식회사 |
항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
|
|
US10391490B2
(en)
|
2013-05-31 |
2019-08-27 |
Celsee Diagnostics, Inc. |
System and method for isolating and analyzing cells
|
|
CA2920666A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
EP3851118A1
(en)
|
2013-10-25 |
2021-07-21 |
Acceleron Pharma Inc. |
Endoglin peptides to treat fibrotic diseases
|
|
WO2015081290A1
(en)
|
2013-11-27 |
2015-06-04 |
Inis Biotech Llc |
Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
|
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量（ｈｍｗ）タウ種およびその用途
|
|
JP2016530244A
(ja)
*
|
2013-12-31 |
2016-09-29 |
ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ |
抗ｖｅｇｆ抗体及びその使用
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
DK3099717T3
(da)
|
2014-01-31 |
2019-07-01 |
Novartis Ag |
Antistofmolekyler med tim-3 og anvendelser deraf
|
|
TWI558399B
(zh)
|
2014-02-26 |
2016-11-21 |
美國禮來大藥廠 |
癌症之組合療法
|
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
CR20160561A
(es)
|
2014-05-01 |
2017-05-03 |
Genentech Inc |
Variantes del anticuerpo anti-factor d y sus usos
|
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
WO2016011052A1
(en)
|
2014-07-14 |
2016-01-21 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
JP7072384B2
(ja)
|
2014-09-15 |
2022-05-20 |
ジェネンテック， インコーポレイテッド |
抗体製剤
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
JP6849590B2
(ja)
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
|
WO2016070051A2
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
MX2017006864A
(es)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
|
|
AU2016262100B2
(en)
|
2015-05-12 |
2021-10-14 |
Syntimmune, Inc. |
Humanized affinity matured anti-FcRn antibodies
|
|
JP2018521979A
(ja)
|
2015-06-03 |
2018-08-09 |
ボストン バイオメディカル， インコーポレイテッド |
癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
|
|
TW201711702A
(zh)
|
2015-06-04 |
2017-04-01 |
應克隆公司 |
使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
EP3353204B1
(en)
|
2015-09-23 |
2023-10-18 |
Mereo BioPharma 5, Inc. |
Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
|
|
CN108137681B
(zh)
|
2015-09-23 |
2024-06-18 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
NZ741780A
(en)
|
2015-10-30 |
2019-11-29 |
Genentech Inc |
Anti-htra1 antibodies and methods of use thereof
|
|
CA3003647A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibody formulations
|
|
SMT202200118T1
(it)
|
2015-11-03 |
2022-05-12 |
Janssen Biotech Inc |
Anticorpi che legano specificamente pd-1 e loro usi
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
BR112018013407A2
(en)
|
2015-12-30 |
2018-12-18 |
Kodiak Sciences Inc. |
antibodies and conjugates thereof
|
|
WO2017119435A1
(ja)
|
2016-01-06 |
2017-07-13 |
株式会社オーダーメードメディカルリサーチ |
高親和性抗ｖｅｇｆ抗体
|
|
KR102293753B1
(ko)
|
2016-01-06 |
2021-08-24 |
오더-메이드 메디컬 리서치 인코포레이티드 |
Vegf 와 nrp1 의 결합을 저해하는 항체
|
|
WO2017165681A1
(en)
|
2016-03-24 |
2017-09-28 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
JP2019513767A
(ja)
|
2016-04-15 |
2019-05-30 |
イーライ リリー アンド カンパニー |
マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法
|
|
CN109069632A
(zh)
|
2016-04-15 |
2018-12-21 |
伊莱利利公司 |
用于治疗结直肠癌的雷莫芦单抗和merestinib的组合
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
EP3448429B1
(en)
|
2016-04-25 |
2021-01-13 |
Syntimmune Inc. |
Humanized affinity matured anti-fcrn antibodies
|
|
EP3463456A1
(en)
|
2016-06-03 |
2019-04-10 |
ImClone LLC |
Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
|
|
CA3029784A1
(en)
|
2016-07-07 |
2018-01-11 |
The European Molecular Biology Laboratory |
Viral polypeptide fragments that bind cellular pol ii c-terminal domain (ctd) and their uses
|
|
EP3481963B1
(en)
|
2016-07-08 |
2025-10-29 |
Genentech, Inc. |
Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
|
|
CN109690315A
(zh)
|
2016-07-08 |
2019-04-26 |
豪夫迈·罗氏有限公司 |
人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
|
|
JP2019523404A
(ja)
|
2016-07-15 |
2019-08-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
全ｖｅｇｆ−ａのレベルを検出するための方法及び手段
|
|
US20210293786A1
(en)
*
|
2016-08-08 |
2021-09-23 |
Konica Minolta, Inc. |
Method Relating to Evaluation of Tumor Tissue of Experimental Animal
|
|
AU2017324983B2
(en)
*
|
2016-09-07 |
2025-03-20 |
Saksin Lifesciences Pvt Ltd |
Synthetic antibodies against VEGF and their uses
|
|
AU2017336867B2
(en)
|
2016-09-29 |
2024-03-14 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Heterodimeric immunoglobulin constructs and preparation methods thereof
|
|
JP2019534888A
(ja)
|
2016-10-28 |
2019-12-05 |
イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ |
癌の治療のための抗ｖｅｇｆｒ−２抗体と抗ｐｄ−ｌ１抗体との組み合わせ
|
|
EP3541383B1
(en)
|
2016-11-16 |
2021-01-06 |
Eli Lilly and Company |
Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
|
|
WO2018093668A1
(en)
|
2016-11-16 |
2018-05-24 |
Eli Lilly And Company |
Therapy for metatastic colorectal cancer using anti-vegfr-2 and anti-vegf-d antibodies
|
|
CA3043652A1
(en)
|
2016-11-18 |
2018-05-24 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
|
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
PL3589754T3
(pl)
|
2017-03-01 |
2023-10-09 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
|
EP3600441A1
(en)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
CN111295245B
(zh)
|
2017-08-29 |
2021-03-16 |
伯乐实验室有限公司 |
用于分离和分析细胞的系统和方法
|
|
WO2019057946A1
(en)
|
2017-09-25 |
2019-03-28 |
F. Hoffmann-La Roche Ag |
MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
|
|
CN107703290A
(zh)
*
|
2017-09-30 |
2018-02-16 |
安徽伊普诺康生物技术股份有限公司 |
一种血管内皮因子检测试剂盒的制备方法
|
|
CN107727847A
(zh)
*
|
2017-09-30 |
2018-02-23 |
安徽伊普诺康生物技术股份有限公司 |
一种血管内皮因子检测试剂盒及其使用方法
|
|
JPWO2019098385A1
(ja)
|
2017-11-20 |
2020-12-24 |
コニカミノルタ株式会社 |
薬剤評価方法
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
CA3090878A1
(en)
|
2018-02-11 |
2019-08-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
|
|
SG11202008242XA
(en)
|
2018-03-02 |
2020-09-29 |
Kodiak Sciences Inc |
Il-6 antibodies and fusion constructs and conjugates thereof
|
|
CA3094444C
(en)
*
|
2018-03-19 |
2023-04-11 |
Pharmabcine Inc. |
Anti-vegfr-2 antibody
|
|
WO2019195770A1
(en)
|
2018-04-06 |
2019-10-10 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|
|
AU2019254237B2
(en)
|
2018-04-16 |
2025-01-30 |
Onquality Pharmaceuticals China Ltd. |
Method for preventing or treating side effects of cancer therapy
|
|
WO2019225777A1
(ko)
|
2018-05-23 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-ror1 항체 및 그 용도
|
|
PE20211916A1
(es)
|
2018-05-24 |
2021-09-28 |
Janssen Biotech Inc |
Agentes aglutinantes del psma y usos de estos
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3813864A4
(en)
|
2018-06-29 |
2022-07-20 |
Gensun Biopharma Inc. |
Antitumor antagonists
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
EP3898673A1
(en)
|
2018-12-21 |
2021-10-27 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
|
US10633693B1
(en)
|
2019-04-16 |
2020-04-28 |
Celsee Diagnostics, Inc. |
System and method for leakage control in a particle capture system
|
|
CN113747944A
(zh)
|
2019-04-19 |
2021-12-03 |
詹森生物科技公司 |
用抗psma/cd3抗体治疗前列腺癌的方法
|
|
TWI879768B
(zh)
|
2019-05-03 |
2025-04-11 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
|
US11273439B2
(en)
|
2019-05-07 |
2022-03-15 |
Bio-Rad Laboratories, Inc. |
System and method for target material retrieval from microwells
|
|
JP7413408B2
(ja)
|
2019-05-07 |
2024-01-15 |
バイオ－ラッド ラボラトリーズ インコーポレイテッド |
自動化された単一細胞処理のためのシステムおよび方法
|
|
US11332546B2
(en)
|
2019-05-21 |
2022-05-17 |
The Regents Of The University Of California |
Protease inhibitory antibodies and methods of use thereof
|
|
WO2020237092A2
(en)
*
|
2019-05-21 |
2020-11-26 |
The Regents Of The University Of California |
Mmp-9 antibodies and methods of use thereof
|
|
EP3990926A4
(en)
*
|
2019-06-26 |
2023-09-13 |
Bio-Rad Laboratories, Inc. |
SYSTEM AND METHOD FOR RECOVERY OF TARGET MATERIAL FROM MICROWELLS
|
|
WO2020260595A1
(en)
|
2019-06-26 |
2020-12-30 |
Oncurious Nv |
Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent
|
|
WO2020263312A1
(en)
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
CN114008075B
(zh)
*
|
2019-07-19 |
2024-08-16 |
神州细胞工程有限公司 |
人源化抗vegf单克隆抗体
|
|
EP4043490B1
(en)
|
2019-07-19 |
2025-08-27 |
Sinocelltech Ltd. |
Humanized anti-vegf fab antibody fragment and use thereof
|
|
JP7315780B2
(ja)
|
2019-07-22 |
2023-07-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
子宮内膜症の非侵襲的診断のための血液バイオマーカーとしてのサブスタンスｐ
|
|
CN114144676A
(zh)
|
2019-07-22 |
2022-03-04 |
豪夫迈·罗氏有限公司 |
S100a6作为血液生物标志物用于子宫内膜异位症的非侵入性诊断
|
|
KR20220024782A
(ko)
|
2019-07-22 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
자궁내막증의 비침습적 진단을 위한 혈액 바이오마커로서의 s100a8
|
|
JP7315781B2
(ja)
|
2019-07-22 |
2023-07-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
子宮内膜症の非侵襲的診断のための血液バイオマーカーとしてのｓ１００ａ１２
|
|
BR112022000172A2
(pt)
|
2019-07-22 |
2022-02-22 |
Hoffmann La Roche |
Métodos para avaliar se uma paciente tem endometriose, para selecionar uma paciente para terapia e para monitorar uma paciente
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
AU2020358854A1
(en)
|
2019-10-03 |
2022-05-26 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
JP7783809B2
(ja)
|
2019-11-15 |
2025-12-10 |
エフ． ホフマン－ラ ロシュ アーゲー |
患者試料における質量分析測定のためのβ－ラクタム抗生物質の誘導体化
|
|
JP7638989B2
(ja)
*
|
2019-11-21 |
2025-03-04 |
ユニティ バイオテクノロジー インコーポレイテッド |
Ｔｉｅ－２に対する抗体および使用方法
|
|
CA3174680A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2021214248A1
(en)
|
2020-04-23 |
2021-10-28 |
F. Hoffmann-La Roche Ag |
Corona nucleocapsid antigen for use in antibody-immunoassays
|
|
JP2023528375A
(ja)
|
2020-05-29 |
2023-07-04 |
２３アンドミー・インコーポレイテッド |
抗ｃｄ２００ｒ１抗体及びその使用方法
|
|
CN116234824A
(zh)
|
2020-06-22 |
2023-06-06 |
阿尔米雷尔有限公司 |
抗il-36抗体及其使用方法
|
|
JP2023531537A
(ja)
|
2020-06-30 |
2023-07-24 |
メンドゥス・ベスローテン・フェンノートシャップ |
卵巣癌ワクチンでの白血病由来細胞の使用
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
EP3943946A1
(en)
|
2020-07-20 |
2022-01-26 |
F. Hoffmann-La Roche AG |
Gdf-15 for predicting the disease severity of a patient with covid-19
|
|
JP2023541627A
(ja)
|
2020-09-14 |
2023-10-03 |
イシュノス サイエンシズ ソシエテ アノニム |
Ｉｌ１ｒａｐに結合する抗体及びその使用
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022081900A1
(en)
*
|
2020-10-15 |
2022-04-21 |
Bioincept, Llc |
Systems, compositions and methods of determining viability of embryos using the same
|
|
US20230406909A1
(en)
|
2020-11-02 |
2023-12-21 |
Roche Diagnostics Operations, Inc. |
Sars-cov-2 nucleocapsid antibodies
|
|
JP2023550028A
(ja)
|
2020-11-13 |
2023-11-30 |
ジェネンテック， インコーポレイテッド |
固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｖｅｇｆ阻害剤を含む方法及び組成物
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
EP4255929A2
(en)
|
2020-12-02 |
2023-10-11 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
JP7637777B2
(ja)
|
2020-12-08 |
2025-02-28 |
ジェネンテック， インコーポレイテッド |
固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｅｇｆｒ阻害剤を含む方法及び組成物
|
|
CA3206304A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Human ccr8 binders
|
|
CA3206124A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
WO2022136650A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Murine cross-reactive human ccr8 binders
|
|
EP4281102A1
(en)
|
2021-01-22 |
2023-11-29 |
Mendus B.V. |
Methods of tumor vaccination
|
|
JP2024504758A
(ja)
|
2021-01-28 |
2024-02-01 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｓｍａ結合タンパク質及びその使用
|
|
AR124914A1
(es)
*
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
Nuevo anticuerpo anti-pad4
|
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
CN112961243B
(zh)
*
|
2021-03-24 |
2022-04-29 |
山东兴瑞生物科技有限公司 |
一种vegf抗体、重组aav病毒及其应用
|
|
WO2022207628A1
(en)
|
2021-03-30 |
2022-10-06 |
F. Hoffmann-La Roche Ag |
Scf as blood biomarker for the non-invasive diagnosis of endometriosis
|
|
WO2022207685A1
(en)
|
2021-04-01 |
2022-10-06 |
F. Hoffmann-La Roche Ag |
Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
EP4330436A1
(en)
|
2021-04-30 |
2024-03-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
|
JP7727015B2
(ja)
|
2021-05-17 |
2025-08-20 |
エフ． ホフマン－ラ ロシュ アーゲー |
腺筋症の非侵襲的診断のための血液バイオマーカーとしてのｓＦＲＰ４
|
|
US20220389120A1
(en)
|
2021-06-03 |
2022-12-08 |
Gensun Biopharma Inc. |
Multispecific antagonists
|
|
TW202309078A
(zh)
|
2021-07-02 |
2023-03-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
|
CA3224180A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
|
WO2023009529A2
(en)
|
2021-07-28 |
2023-02-02 |
Trustees Of Boston University |
Novel polypeptides and uses thereof
|
|
EP4423122A1
(en)
|
2021-10-26 |
2024-09-04 |
F. Hoffmann-La Roche AG |
Monoclonal antibodies specific for sars-cov-2 rbd
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
EP4444910A4
(en)
|
2021-12-10 |
2025-11-05 |
Bio Rad Laboratories Inc |
Compositions, processes and systems for the treatment of samples with functionalized particles of adjustable morphology
|
|
WO2023144973A1
(ja)
|
2022-01-27 |
2023-08-03 |
中外製薬株式会社 |
抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物
|
|
WO2023142996A1
(zh)
|
2022-01-28 |
2023-08-03 |
上海岸阔医药科技有限公司 |
预防或治疗与抗肿瘤剂相关的疾病或病症的方法
|
|
KR20240150493A
(ko)
|
2022-02-21 |
2024-10-15 |
온퀄리티 파마슈티컬스 차이나 리미티드 |
화합물 및 그 용도
|
|
CN116925234B
(zh)
*
|
2022-04-02 |
2024-05-31 |
合肥星眸生物科技有限公司 |
一种编码抗vegf-a和ang-2双特异性抗体的aav载体
|
|
WO2023198848A1
(en)
|
2022-04-13 |
2023-10-19 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
EP4519285A1
(en)
|
2022-05-03 |
2025-03-12 |
F. Hoffmann-La Roche AG |
Hiv gp41 variants for immunodiagnostic assays
|
|
CN119404103A
(zh)
|
2022-06-23 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
用于诊断子宫内膜异位症及用于对子宫内膜异位症的分期进行分类的方法
|
|
US20260016487A1
(en)
|
2022-07-22 |
2026-01-15 |
Roche Diagnostics Operations, Inc. |
Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
|
|
JP2025524025A
(ja)
|
2022-07-22 |
2025-07-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
多嚢胞性卵巣症候群の診断のための（血液）バイオマーカーとしてのロイコトリエンａ４ヒドロラーゼ（ｌｔａ４ｈ）
|
|
US20260036594A1
(en)
|
2022-07-22 |
2026-02-05 |
Roche Diagnostics Operations, Inc. |
Fibroblast growth factor binding protein 1 (fgfbp1) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
|
|
CN115850470B
(zh)
*
|
2022-12-12 |
2023-07-07 |
三门峡市眼科医院 |
Vegf抗体及其应用
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025026908A1
(en)
|
2023-07-28 |
2025-02-06 |
Roche Diagnostics Gmbh |
Serum epha1 as biomarker for endometriosis
|
|
WO2025049972A1
(en)
|
2023-09-01 |
2025-03-06 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
TW202541837A
(zh)
|
2023-12-08 |
2025-11-01 |
日商安斯泰來製藥公司 |
含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025128837A1
(en)
*
|
2023-12-13 |
2025-06-19 |
Systimmune, Inc. |
Anti-claudin18.2 antibody-camptothecin drug conjugate and pharmaceutical use thereof
|
|
WO2026019994A1
(en)
|
2024-07-19 |
2026-01-22 |
Genentech, Inc. |
Methods and compositions comprising a shp2 inhibitor and an egfr inhibitor
|